How it works
Sermorelin is the biologically active fragment of growth hormone releasing hormone. It stimulates the pituitary to release growth hormone, which is why it was originally used to test whether a pituitary was capable of responding.
Because it works through the pituitary rather than replacing growth hormone directly, its effect is bounded by what the gland can produce. That is the argument usually made for it being gentler than growth hormone. It is a reasonable argument and it is not the same as evidence of benefit.
What the evidence shows
Sermorelin's evidence base is in diagnostic testing of growth hormone deficiency and in paediatric growth, which is what it was approved for. The adult anti-ageing, body composition and sleep claims it is now sold for are not supported by controlled trials.
Typical dosing
The historical approved dosing was for diagnostic and paediatric use. Current compounded protocols for adult wellness use are not derived from trials.
Reported side effects
Injection site reactions were the most commonly reported effect during its approved use. Flushing and headache were also recorded. Rates for current off-label protocols are not established.
Labelled warnings and contraindications
- Withdrawal from the US market in 2008 was a commercial decision, not a safety action. That distinction is real and is also routinely overstated by clinics selling it.
- FDA added sermorelin to the Category 2 bulk drug substances list in 2023, which restricts lawful compounding.
- The general cautions around raising GH and IGF-1 in adults who are not deficient apply here as they do to the secretagogues.
- Prohibited by the World Anti-Doping Agency.
Legal status and sourcing
There is no FDA-approved sermorelin product on the US market. Everything currently prescribed is compounded.
The 2023 Category 2 designation puts that compounding on contested footing. A clinic offering it today is operating in a narrower space than it was a few years ago.
What it costs
Compounded sermorelin is generally priced inside a clinic programme rather than sold separately, so a standalone monthly figure would mislead more than it informed. The 2023 Category 2 listing has also made availability uneven between clinics, which moves pricing around.
How confident anyone can be
Moderate for the pharmacology, low for the reasons it is actually being sold. That it stimulates growth hormone release is well established. That doing so benefits a healthy adult is not.